Clinical Trials
10 trialsNCT07318051 2026-01-15
SCORE
Natera, Inc.
Recruiting
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT05697198 2025-03-06
PREFER
Labcorp Corporation of America Holdings, Inc
Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT05708950 2023-07-13
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
Phase 1/2 Unknown
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT03896958 2020-12-04
PIONEER
SpeciCare
Unknown
NCT01234012 2015-03-10
Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1
ImmunoFrontier, Inc.
Phase 1 Completed